A Phase 3 interventional study of Evolocumab and Placebo to Evolocumab in Hypercholesterolemia, Mixed Dyslipidemia and Type 2 Diabetes, sponsored by Amgen. Completed at 66 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 13th largest by enrollment, is one of 4 that started in 2016, is one of 22 in phase 3, and was the 26th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 424 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 13th largest by enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2016, is one of 22 in phase 3, and was the 27th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.
This study will enroll adults with type 2 diabetes mellitus and elevated LDL-C or non-high-density lipoprotein cholesterol (non-HDL-C) levels on a stable, maximally tolerated statin dose of at least moderate-intensity at signing of the informed consent; statin therapy must remain unchanged during screening and the remainder of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
Drug: Placebo to Evolocumab
Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection with an automated mini doser
Also known as: Repatha, AMG 145
Administered by subcutaneous injection with an automated mini doser
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in LDL-C at Week 12
Time frame: Baseline and week 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Total Cholesterol at Week 12
Time frame: Baseline and week 12
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)
Time frame: Weeks 10 and 12
Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)
Time frame: Week 12
Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Lipoprotein(a) at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in VLDL-C at Week 12
Time frame: Baseline and week 12
Of 853 patients screened, a total of 424 participants were randomized at 58 centers in Belgium, Canada, Italy, Mexico, Poland, Spain and the United States from 17 May 2016 to 05 May 2017.
| Milestone | Placebo | Evolocumab |
|---|---|---|
| Started | 143 | 281 |
| Received study drug | 141 | 280 |
| Completed | 138 | 279 |
| Not completed | 5 | 2 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -0.84 ± 1.76 | -64.98 ± 1.31 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 12 | -1.14 ± 1.92 | -54.28 ± 1.42 |
| mg/dL | Placebo | Evolocumab |
|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -8.3 ± 2.2 | -75.5 ± 1.6 |
| mg/dL | Placebo | Evolocumab |
|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -8.6 ± 2.3 | -64.4 ± 1.7 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12 | -0.05 ± 1.63 | -56.62 ± 1.21 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | -0.60 ± 1.79 | -46.89 ± 1.33 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12 | 2.31 ± 1.58 | -50.17 ± 1.18 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | 1.78 ± 1.73 | -40.34 ± 1.29 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12 | -1.13 ± 1.24 | -42.19 ± 0.92 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12 | -1.23 ± 1.36 | -34.97 ± 1.01 |
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L) | 14.8 (9.8 to 21.8) | 92.7 (89.0 to 95.2) |
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L) | 15.4 (10.2 to 22.6) | 84.5 (79.5 to 88.5) |
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12 | 0.7 (0.1 to 4.1) | 84.2 (79.5 to 88.1) |
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12 | 0.8 (0.1 to 4.2) | 65.5 (59.4 to 71.1) |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12 | 9.63 ± 3.29 | -30.87 ± 2.43 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 | 7.38 ± 3.06 | -25.18 ± 2.28 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | 6.61 ± 2.94 | -12.64 ± 2.19 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | 4.81 ± 3.41 | -8.90 ± 2.52 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12 | -2.57 ± 1.25 | 7.23 ± 0.93 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | -1.41 ± 1.38 | 5.96 ± 1.02 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12 | 3.42 ± 2.57 | -13.64 ± 1.89 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in VLDL-C at Week 12 | 3.02 ± 2.94 | -10.31 ± 2.15 |
Collected over From the first dose of study drug (placebo or evolocumab) to week 12.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/141 (0%) | 2/141 (1.4%) | 19/141 (13.5%) |
| Evolocumab | 1/280 (0.4%) | 14/280 (5%) | 37/280 (13.2%) |
| Event | Placebo | Evolocumab |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/141 | 4/280 |
| Coronary artery diseaseCardiac disorders | 0/141 | 2/280 |
| Peptic ulcerGastrointestinal disorders | 1/141 | 0/280 |
| Osteomyelitis chronicInfections and infestations | 1/141 | 0/280 |
| Atrial fibrillationCardiac disorders | 0/141 | 1/280 |
| Sudden cardiac deathGeneral disorders | 0/141 | 1/280 |
| CellulitisInfections and infestations | 0/141 | 1/280 |
| Gastroenteritis viralInfections and infestations | 0/141 | 1/280 |
| PneumoniaInfections and infestations | 0/141 | 1/280 |
| Pneumonia bacterialInfections and infestations | 0/141 | 1/280 |
| Event | Placebo | Evolocumab |
|---|---|---|
| HypertensionVascular disorders | 0/141 | 11/280 |
| Diabetes mellitusMetabolism and nutrition disorders | 5/141 | 8/280 |
| DiarrhoeaGastrointestinal disorders | 4/141 | 6/280 |
| Viral upper respiratory tract infectionInfections and infestations | 4/141 | 5/280 |
| Urinary tract infectionInfections and infestations | 2/141 | 6/280 |
| HeadacheNervous system disorders | 3/141 | 6/280 |
| PharyngitisInfections and infestations | 3/141 | 0/280 |
| Back painMusculoskeletal and connective tissue disorders | 3/141 | 2/280 |
All randomized participants
| Age, Continuous(years) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 62.3 ± 8.5 | 62.5 ± 8.5 | 62.5 ± 8.5 |
| Age, Customized(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| < 65 years | 86 | 159 | 245 |
| 65 - < 85 years | 57 | 122 | 179 |
| ≥ 85 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Female | 65 | 121 | 186 |
| Male | 78 | 160 | 238 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 24 | 54 | 78 |
| Not Hispanic or Latino | 119 | 227 | 346 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 8 | 15 |
| Asian | 2 | 4 | 6 |
| Black (or African American) | 32 | 41 | 73 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| White | 102 | 223 | 325 |
| Multiple | 0 | 1 | 1 |
| Other | 0 | 2 | 2 |
| Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C) Level(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| < 130 mg/dL | 108 | 213 | 321 |
| ≥ 130 mg/dL | 35 | 68 | 103 |
| LDL-C Concentration(mg/dL) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 110.4 ± 33.0 | 108.6 ± 31.0 | 109.2 ± 31.6 |
| Non-High-density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 145.5 ± 33.9 | 144.6 ± 34.9 | 144.9 ± 34.5 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Aug 2017, 14 months.
Results were first posted in Aug 2018, 1 year after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab